In a patient with chronic kidney disease stage IV and chronic hyperkalemia who was started on Loketma (sodium zirconium cyclosilicate) 10 mg twice daily and now has acute kidney injury with impaired renal function and hyperkalemia, could the twice‑daily Loketma be causing the AKI, or should the dose be increased to 15 mg twice daily?

Lokelma is NOT Causing the AKI and Should Be Increased to 15 mg Once Daily

In this patient with CKD stage IV, chronic hyperkalemia, and new AKI with persistent hyperkalemia (K+ 5.8 mEq/L), you should increase Lokelma to 15 mg once daily rather than discontinue it—there is no evidence that Lokelma causes AKI, and the persistent hyperkalemia requires dose escalation.

Why Lokelma is Not the Culprit

Lokelma (sodium zirconium cyclosilicate) is a non-absorbed potassium binder that works entirely within the GI tract by exchanging sodium for potassium 1. It does not undergo systemic absorption and therefore has no direct nephrotoxic mechanism. The FDA label contains no warnings about AKI or worsening renal function 1.

Key evidence supporting safety in advanced CKD:

• Long-term studies specifically in patients with severe CKD (eGFR <30 mL/min/1.73 m²) showed that 82% achieved and maintained normokalemia over 12 months without evidence of renal function deterioration 2
• In a 12-month open-label trial of 751 patients (74% with eGFR <60), Lokelma maintained normokalemia with mean serum potassium of 4.7 mmol/L, and no renal toxicity was reported 3

The Real Issue: Inadequate Dosing for Persistent Hyperkalemia

Your patient's potassium remains elevated at 5.8 mEq/L despite being on 10 mg twice daily (which appears to be an off-label dosing schedule—the FDA-approved regimen is once daily maintenance dosing) 1.

The correct approach per FDA labeling:

• Maintenance dosing should be 10 g ONCE daily (not twice daily) 1
• When potassium remains elevated on 10 g once daily, up-titrate in 5 g increments at weekly intervals 1
• Maximum maintenance dose is 15 g once daily 1
• The dose range of 5 g every other day to 15 g daily allows for individualized titration based on potassium levels 1

Specific Dosing Recommendation

Switch from 10 mg twice daily to 15 mg once daily and recheck potassium in one week. This aligns with:

• FDA-approved maintenance dosing strategy 1
• The patient's persistent hyperkalemia requiring dose escalation
• Evidence that doses up to 15 g daily are safe and effective in advanced CKD 2, 3

Important Caveats About Sodium Load

Each 5 g dose contains approximately 400 mg of sodium 1. At 15 g daily, this represents ~1,200 mg of sodium, though the extent of absorption is unknown 1.

Monitor for:

• Edema (more common at 15 g daily dosing) 1
• Fluid overload in this CKD stage IV patient
• Interdialytic weight gain if the patient progresses to dialysis 1

The FDA label specifically notes edema was "generally mild to moderate" and more common at 15 g daily, but this did not lead to treatment discontinuation in most patients 1. Consider adjusting dietary sodium and increasing diuretics if edema develops 1.

What's Actually Causing the AKI?

Look elsewhere for the AKI etiology:

• Volume depletion
• Nephrotoxic medications (NSAIDs, contrast, antibiotics)
• Urinary obstruction
• Worsening of underlying kidney disease
• Acute illness with decreased oral intake

The timing of AKI onset relative to Lokelma initiation would be coincidental, not causal.

Why Not Dialysis?

With K+ 5.8 mEq/L, this is moderate hyperkalemia, not immediately life-threatening. Recent guidelines emphasize using potassium binders to manage chronic hyperkalemia and avoid emergency dialysis 4. The goal is to optimize Lokelma dosing to maintain normokalemia and potentially preserve residual renal function longer.

Bottom line: Increase Lokelma to 15 mg once daily, investigate other causes of AKI, monitor for edema, and recheck potassium in one week.